ANDROGEN REPLACEMENT THERAPY MARKET ANALYSIS

Androgen Replacement Therapy MarketSize and Trends

The Global androgen replacement therapy market is estimated to be valued at US$ 2,276.6 Mn in 2023 and is expected to exhibit a CAGR of 7.8% during the forecast period (2023-2030).

Figure 1. Global Androgen Replacement Therapy Market Share (%), By Distribution Channel, 2023

Market Trends

Introduction of newer products in the market

The increasing introduction of newer products can drive the growth of the global androgen replacement therapy market. For instance, in June 2022, Halozyme Therapeutics, Inc., a U.S.-based biotechnology company, announced the commercial launch of TLANDO (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of  testosterone (primary or hypogonadotropic hypogonadism).

Among all the segmentations, the product type segment has the highest potential due to the increasing partnerships and collaborations across the world over the forecast period. For instance, on April 4, 2023, PeterMD, a telemedicine provider in North America focusing on Testosterone Replacement Therapy and Male Hormone Optimization Therapy, announced a partnership with The Beverly Hills Anti-aging Center for Men and Women & Advanced Nutrition and Hormone-Based Gynecology, a U.S.-based healthcare provider, to launch PetraMD, female focused Hormone Replacement Therapy telemedicine clinic which will manufacture hormone gels and creams.